President Donald Trump today signed an executive order on healthcare. The order will allow businesses to form associations that will have the ability to purchase health coverage from across state lines.
President Donald Trump today signed an executive order on healthcare. The order will allow businesses to form associations that will have the ability to purchase health coverage from across state lines.
Trump said that the ability to purchase such plans would be “Very, very powerful for our nation and very good for a lot of people.” The order also includes provisions for the creation of health plans that will provide short-term, limited-duration coverage, and for exploration of how employers might use health reimbursement arrangements, which are plans that reimburse employees for medical expense paid for out of pocket.
Senator Rand Paul (R-Kentucky) said that “what I believe is the biggest free market reform of healthcare in a generation” that would “…allow millions of people to get insurance across state lines and at an inexpensive price.” Vice President Mike Pence also praised the executive order, saying that it was a “Critical step to lower the cost of health insurance for working Americans.”
While today’s executive order may not be the full repeal of the Affordable Care Act (ACA) that Republicans have promised their supporters, Trump made it clear that today’s effort was part of a larger push to overhaul healthcare: “I just keep hearing repeal, replace; repeal, replace. Well, we’re starting that process,” he said. “I believe we have the votes to do block grants” at a later time, he went on, apparently referring to a plan similar to the one proposed in the Graham-Cassidy healthcare reform bill that recently failed to garner enough support to move to a Senate vote.
Trump also suggested that the ACA individual market would continue to lose participation from insurers, predicting that half of all counties in the nation would have only 1 insurer participating in the ACA health insurance exchanges, and that others would have none. Allowing associations to purchase insurance plans across states would mean that “they will have so many options,” and that competition among plans would be “staggering.”
The president also indicated that the coming months would see his administration taking further measures related to healthcare and to the economy at large. These measures, he promised, would include “massive” tax cuts.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
British Columbia’s Biosimilar Policy Shows No Impact on Hospital Visits
May 28th 2025Despite a dramatic shift toward biosimilar use following British Columbia’s policy, researchers found no rise in hospital visits or complications, underscoring the real-world reliability of etanercept biosimilars in managing inflammatory arthritis.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.